Institute Of Cardiology & Internal Diseases, Kazakhstan Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2003
NCT02503865
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Institute Of Cardiology & Internal Diseases, Kazakhstan

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 3)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Liver Cirrhosis (Phase 3)

Metabolic Syndrome (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 7